Clinical Trial Update: Phase I Study of [177Lu]Lu-NNS309 in Patients With Pancreatic, Lung, Breast and Colorectal Cancers [Phase 1]

View source ↗

Summary

A Phase I trial evaluating [177Lu]Lu-NNS309, a radiopharmaceutical, in multiple advanced cancers including pancreatic ductal adenocarcinoma, non-small cell lung…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Breast Cancer Hr-positive
• Colorectal Cancer
• Non-small Cell Lung Cancer
• Pancreatic Ductal Adenocarcinoma
• Triple-negative Breast Cancer

Drugs mentioned

• [177Lu]Lu-NNS309 (Lutetium-177 labeled NNS309)

Snippet

Sponsor: Novartis Pharmaceuticals | Conditions: Pancreatic Ductal Adenocarcinoma, Non-small Cell Lung Cancer | Phase 1 | Status: RECRUITING